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Abstract
Current schemes used to serotype Vibrio vulnificus are based 
on direct bacterial agglutination using polyclonal rabbit 
antisera. During the course of serotyping Louisiana V. 
vulnificus isolates we failed to observe a reproducible 
agglutination profile for these isolates. The major 
obstacle in producing serovar specific sera has been the 
failure to produce high titered anti-LPS sera in rabbits. 
Anti-LPS serum from rabbits immunized with formalin-killed, 
heat-killed, or acetone dried whole cell vaccines and LPS- 
carrier conjugates uniformly produced titers < 320. 
Separation of anti-LPS activity from whole sera by affinity 
chromatography also yielded low titered antisera. A typing 
system predicated on the detection of LPS-associated O 
antigens using monoclonal antibodies (Mab) is proposed for 
V. vulnificus. Hybridomas have been established which 
produce antibodies that react with LPS purified from V. 
vulnificus. V. damsela. and V. hollisae. Vibrio vulnificus 
shows considerable heterogeneity within the genus. Twenty- 
four Mabs produced to date, react with 10 of 16 (61%) of V. 
vulnificus strains tested by LPS ELISA. Monoclonal 
antibodies react more strongly with the translucent than the 
opaque phenotype o'f V. vulnificus using whole cell ELISA. 
Monoclonal antibodies reactive by LPS ELISA with V. damsela 
and V. hollisae LPS are non-reactive with LPS prepared from 
V. vulnificus.
Introduction
In recent years there has been a dramatic increase in 
the incidence of fulminate infections caused by Vibrio 
vulnificus. Since these infections may be rapidly fatal, 
prompt diagnosis and treatment are essential. Of equal 
importance is the monitoring of both the marine environment 
and seafood to reduce the risk of infection.
Organisms belonging to the genus Vibrio have been known 
to cause disease in humans for many years. Vibrio cholerae. 
the etiologic agent of classical Asiatic cholera, was among 
the first enteric pathogens to be isolated and 
characterized. Due to the extreme virulence and wide 
distribution of V. cholerae in nature, it has historically 
been the most thoroughly studied member of the genus Vibrio.
As serological studies of V. cholerae became possible, 
the members of the genus Vibrio which did not type in V. 
cholerae typing sera (0-Group 1 or Group 01's) were 
dismissed as "non-agglutinable vibrios" (NAG's) or as "non­
cholera vibrios" (NCV's) (Blake et al. 1980; Farmer et al.
1985). The grouping of vibrios into such a category, based 
on the absence of a serological reaction, was unsatis­
factory. The reports of human infection caused by halo- 
philic non-cholerae Vibrios continued to accumulate in the 
literature (Blake et al. 1980). Several different Vibrio 
species have been identified among these pathogenic non- 
cholerae vibrios. In addition to being distinct biological
1
2entities, these organisms were found to have unique 
pathogenic properties. At the present time, ten species in 
the genus Vibrio have been isolated from clinical specimens 
(Table 1).
In the early 1970's there were numerous reports of a 
non-cholera Vibrio that was associated with sepsis and soft- 
tissue infections (Roland 1970; Zide et al. 1974; 
Thorsteinsson et al. 1974; Fernandez and Pankey 1975; Hollis 
et al. 1976). These infections were characterized by either 
primary septicemia or intense local tissue swelling followed 
by necrosis in infected wounds. This pattern of soft tissue 
destruction or primary septicemia was strikingly different 
from the gastroenteritis and diarrhea seen with V. cholerae 
or V. parahaemolvticus (Roland 1970; Zide et al. 1974; 
Thorsteinsson et al. 1974; Fernandez and Pankey 1975; Hollis 
et al. 1976)(Table 1).
3TABLE 1. Vibrio species isolated from clinical specimens 
and their most common associated diseases.
Oraanism Disease(s)
V. alcrinolvticus Wound infection, otitis
V. cholerae Gastroenteritis
V. damsela Wound infection,septicemia
V. fluvialis Gastroenteritis
V. furnissii Gastroenteritis
V. hollisae Gastroenteritis, septicemia
V. metschnikovii Rare; urine, blood
V. mimicus Gastroenteritis, otitis
V. oarahaemolvticus Gastroenteritis, wound inf.
V. vulnificus Wound infection, septicemia
4This new organism was at first thought to be a variant 
of V. parahaemolvticus (Roland 1970? Zide et al. 1974).
Upon closer scrutiny it was found to have several unique 
characteristics, the most obvious of these was the ability 
to ferment lactose. These organisms were found to be ONPG 
positive (produce B-galactosidase) 75% of the time compared 
to V. parahaemolvticus. which is positive only 5% of the 
time (Farmer et al. 1985). The capacity to ferment lactose 
led to these isolates being referred as the L+ Vibrios 
(Hollis et al. 1976).
The incidence of L+ Vibrio associated disease began to 
rise as this organism was recognized as a distinct pathogen. 
By 1980 reports of L+ Vibrio infections from the United 
States, Japan, Belgium, and Australia had established L+ 
Vibrios as a pathogen, and had brought the name V. 
vulnificus into widespread use (Matsuo et al. 1978; Mertens 
et al. 1979; Ghosh and Bowen 1980). Briefly, (1970-1976) V. 
vulnificus was referred to as a variant of V. 
parahaemolvticus (Roland 1970; Zide et al.,1974). By 1976, 
these Lac (+) organisms were recognized as a new species and 
(1976-1979) were assigned to the genus Beneckae as Beneckea 
vulnifica (Reichelt et al. 1976). Farmer (1979) proposed 
that the organism be reassigned to the genus Vibrio as 
Vibrio vulnificus in 1979, and that designation has been 
accepted by most workers. By 1979, Blake et al. (1980)
reported that 41 V. vulnificus infections had been described 
in the literature.
Vibrio vulnificus is widely distributed in the marine 
environment. Oliver et al. (1982, 1983) have done extensive 
environmental studies. Their studies have shown that Vibrio 
species account for 26% to 30% of all bacteria isolated. A 
very small proportion of these vibrios were identified as V. 
vulnificus. Of all the Vibrio isolates that Oliver et al. 
recovered, only 4.2% fermented lactose, and of the Lac (+) 
isolates only 20% were identified to the species level as V. 
vulnificus. Vibrio vulnificus was most commonly isolated 
from animals (84% from clams), and 82% of these isolates 
were found to be pathogenic for mice. These data were 
obtained from 80 collection sites which ranged from Maine to 
Florida on the Atlantic coast (Oliver et al. 1982; Oliver et 
al. 1983). A survey of west coast estuaries in 1984 
correlated with the east coast data in that V. vulnificus 
was isolated from 6% of the water specimens (Kaysner et al. 
1987) . Both studies concluded that V. vulnificus was 
present in very low numbers in each of the marine sites 
tested.
The presence of V. vulnificus in the marine environment 
is dependent on the water temperature and salinity. A study 
by Kelly (1982) has shown that over a 12 month period V. 
vulnificus was found to be most often isolated from areas of 
low salinity during the warmer months of the year (May
6through October). Vibrio vulnificus has a growth 
temperature optimum of 37° C. Studies have shown that V. 
vulnificus was isolated most frequently in the water along 
the Gulf Coast during the summer months when temperatures 
consistently remain above 25° C. In a study of the recovery 
rate for V. vulnificus 100% of Galveston Island sites were 
positive for V. vulnificus in September, however, by 
December all of these site were negative for V. vulnificus 
(Kelly, 1982).
Historically oysters were not harvested during the 
summer months. In recent years, however, oysters and other 
seafood have been harvested on a year-round basis.
Harvesting oysters during the summer months, when the water 
from which they are being taken contains the highest 
concentration of V. vulnificus, increases human exposure to 
V. vulnificus. Since outbreaks of foodborne vibriosis in 
humans follow consumption of raw oysters or other seafood 
harvested from the Gulf Coast it has been inferred that this 
change in harvesting is responsible for the increase in V. 
vulnificus infection. The recent recognition of V. 
vulnificus as an important human pathogen demonstrates that 
the balance between health and disease can be drastically 
altered by seemingly small changes in the way man interacts 
with his environment.
Oysters are filter feeders that concentrate food 
material from seawater. Kelly and Dinuzzo (1985) showed
7that V. vulnificus was concentrated by oysters when they 
were exposed to water inoculated with V. vulnificus. When 
V. vulnificus was removed from the water the oysters rapidly 
cleared their V. vulnificus burden. These findings suggest 
that oysters may become reservoirs for V. vulnificus in 
contaminated waters but, that V. vulnificus may not be 
growing within the oyster (Kelly and Dinuzzo, 1985). 
Presently, the process of depuration is being investigated 
as a method of sanitizing oysters.
There is no apparent difference between environmental 
and clinical isolates when biochemical characteristics or 
antibiotic susceptibility profiles are compared (Johnson and 
Calia 1981; Tison and Kelly 1986). Genetic studies revealed 
that clinical and environmental isolates of V. vulnificus 
have a base composition of 47-48 mol% guanine + cytosine and 
share > 85% DNA homology by hybridization (Tison and Siedler 
1981).
Although V. vulnificus infections have been documented 
in the literature since the early 1970's, it was not until 
the mid- 1980's that these infections received public 
attention. Blake (1983) urged persons with liver disease or 
immunologic disorders to abstain from eating raw seafood.
In April of 1985, the Food and Drug Administration (FDA) 
published a warning to patients with liver disease and other 
chronic diseases about V. vulnificus infections (FDA Drug 
Bulletin 1985). It is unclear whether the increase in
reported V. vulnificus infections during the last two years 
represents an actual increase in incidence or an increase in 
the recognition and reporting of these infections.
Disease produced by V. vulnificus usually falls into 
one of two categories, a local dermal infection at the site 
of an injury (puncture wound) or a disseminated primary 
septicemia. The majority of V. vulnificus infections 
involve exposure to seawater or raw seafood (Blake 1979; 
Bonner 1983; Johnston 1985). However, several cases have 
been reported where the infection was acquired in inland 
areas, and no contact with the marine environment could be 
established (Mertens et al. 1979; Tacket 1984). These 
inland isolates were recovered from waters with salinity 
levels sufficient to support the growth of V. vulnificus.
Among Vibrio pathogens, the production of skin lesions 
and primary septicemia is relatively infrequent. V. 
parahaemolvticus and V. cholerae Non-01 may produce wound 
infections and septicemias, however, they most commonly 
produce gastroenteritis (Farmer et al. 1985). A recently 
recognized Vibrio. V. hollisae.' causes severe diarrhea. 
However, cases of V. hollisae bacteremia have been reported 
(Morris et al. 1982; Farmer 1985; Rank et al. 1988). In one 
instance, V. hollisae produced a bacteremia in a patient 
with chronic active hepatitis. This patient had eaten 
dried, salted fish. However, V. hollisae could not be 
recovered from fish purchased at the same store. This
patient was also being treated with oral iron for chronic 
anemia (Rank et al. 1988). Vibrio damsela and V. 
alginolvticus cause wound infections. Although common in 
the marine environment, V. alainolyticus is a rare pathogen. 
Vibrio damsela was first recognized as a fish pathogen. Of 
twenty-two isolates studied by the Centers for Disease 
Control, Atlanta, Ga. (CDC), seven were from fish, and ten 
were recovered from wound infections in humans (Love et al. 
1981; Morris et al. 1982; Farmer et al. 1985; Clarridge and 
Daum 1985).
A ten year longitudinal study of Vibrio infections in a 
Gulf Coast community was reported by Bonner in 1983.
Although this study spanned ten years, only 23 Vibrio 
isolates, were recovered. Of the twenty-three isolates 12 
were V. vulnificus (4 from wound infections, 5 from wound 
infections with bacteremia, and 3 from bacteremic patients), 
5 were V. parahaemolvticus. 4 were V. cholerae Non-01, and 2 
were V. alainolyticus. Most of these infections occurred 
from April to October when the weather was the warmest 
(Bonner et al., 1983).
The dermal lesions caused by V. vulnificus described by 
Beckman et.al. were characterized by acute cellulitis, which 
spread from the initial wound into adjacent tissue (Beckman 
et al. 1981). The superficial dermis becomes separated from 
the underlying tissue by the formation of a non-inflammatory 
subepidermal bullae or vesicle. The dermis becomes necrotic
but shows no inflammation. The vesicles contain many 
organisms, especially at their base but, like the dermis, no 
inflammation is seen. The organisms are found extending 
down into the subcutaneous tissues where extensive 
cellulitis accompanied by inflammatory infiltration leads to 
tissue damage and edema. Edema, by putting pressure on the 
blood vessels, interrupts the flow of blood and enhances 
necrosis. Surgical intervention is often necessary to 
restore blood flow and save adjacent healthy tissue from 
further damage. There is also a tendency for the organisms 
to be found around the blood vessels (Beckman et al. 1981).
Vibrio vulnificus produces a number of virulence factors 
that aid in establishing dermal infection: siderophores, 
proteases, collagenases, phospholipase, lysophospholipase, 
cytolysins, hemolysins, and extracellular toxins (Simpson et 
al. 1983; Kothary and Kreger 1985; Smith and Merkel 1982; 
Testa et al. 1984; Gray and Kreger 1985; Tison and Kelly 
1984; Kreger and Lockwood 1981).
A second form of V. vulnificus infection is primary 
septicemia. This septicemia is characterized by general 
malaise, chills, fever, vomiting, hypotension and, in some 
cases, diarrhea (Blake et al. 1980). Within forty-eight 
hours following onset of a V. vulnificus infection cutaneous 
lesions appear, most often on the lower extremities (Bonner 
et al. 1983). These lesions are similar to the lesions 
observed in wound infections. It has been suggested that
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these cutaneous lesions are caused by the hematogenous 
spread of the organism (Blake et al. 1980; Bonner et al. 
1983). This is supported by the work of Johnston et al. 
(1985) which shows that chronic liver disease, especially 
cirrhosis, hematopoietic disorders, chronic renal disease, 
alcoholism, the use of antacids or cimetidine (ie., TagametR 
and probably others such as ZantacR) and the use of 
immunosuppressive drugs are strongly associated with V. 
vulnificus septicemia. Exposure to sea water or injury 
while handling raw shellfish does not show a positive 
correlation with primary septicemia. There is, however, a 
strong positive correlation between consumption of raw 
oysters and septicemia. The point of entry for the 
infectious agent in cases of primary septicemia seems to be 
a break in the gastrointestinal tract, such as an ulcer, 
followed by the consumption of contaminated raw seafood. 
Poliak et al. (1983) recovered V. vulnificus from the blood 
and stool of an alcoholic patient with primary septicemia. 
They also detected anti-V. vulnificus antibody in the serum 
of this victim. In the ten year survey of vibriosis in Gulf 
Coast community, noted earlier, Bonner, et al. (1983) 
reported that only a small percentage of the patients with 
severe diarrhea produced stool specimens from which Vibrio 
species could be isolated. MacConkey's agar was sufficient 
to recover 2 of the 3 isolates from stool specimens, 
although the recommended medium is TCBS agar.
Seventy-five percent of patients with primary 
septicemia suffered from some form of liver disease such as: 
hemochromatosis, cirrhosis or hepatoma. Many of the 
remaining patients had other serious diseases: alcoholism, 
thalassemia, diabetes and leukemia or other malignancies 
(Blake et al. 1980). Increased serum iron levels in 
victims, coupled with the fact that V. vulnificus produces 
siderophores which acquire iron from host iron sequestering 
proteins such as haptoglobin, hemoglobin, hematin, 
hemoplexin, lactoferrin, methemoglobin (Simpson and Oliver 
1983; Andrus et al. 1983; Helms et al. 1984) has led to 
investigations into the relationship of V. vulnificus 
disease to serum iron levels. Wright, et.al.(1981), found 
that increasing the serum iron level in mice by parental 
injection of iron compounds decreased the LDS0 from 106 cells 
to 1.1 cells. Elevated serum iron levels also impair some 
host defense mechanisms (Weinberg 1978), and V. vulnificus 
appears to be more resistant to the bactericidal properties 
of normal serum than are other Vibrio species (Carruthers et 
al. 1981; Tamplin et al. 1983; Johnson et al. 1984; Ward et 
al. 1986).
In many instances, the primary source of the infectious 
agent can not be identified. Tacket et al.(1984), reported 
a wound infection in a patient exposed to water from a 
brackish inland creek but, without exposure to seafood or 
seawater. Mertens et al. (1979) described a fatal case of
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septicemia in which the victim with acute enteritis claimed 
no recent exposure to the sea. It is also possible for the 
presenting symptoms to be different from those described 
above for primary septicemia. Kelly and McCormick (1981), 
report a case of fatal septicemia in which the presenting 
symptom was lower leg pain. In each of the latter cases 
there was a history of diarrhea preceding the onset of acute 
symptoms. Kelly also reports a case of pneumonia caused by 
V. vulnificus in a drowning victim (Kelly and Avery 1980).
A case of acute endometritis caused by V. vulnificus 
occurred in a patient who had no history of raw seafood 
consumption, however, she admitted to having engaged in 
sexual intercourse while "swimming" in the Gulf of Mexico 
(Tison and Kelly 1984).
At present, the clinical pattern of disease production 
has been described thoroughly. Two major obstacles remain 
in the clinical management of V. vulnificus infections. 
First, education of the public so that these infections are 
brought promptly to the attention of the medical community. 
Second, increasing the awareness of the primary care 
physicians, in endemic areas, to insure that the possibility 
of V. vulnificus is considered in the differential 
diagnosis of septicemias and wound infections where a link 
to the marine environment is known (FDA 1988).
The laboratory identification of V. vulnificus 
infections is both time consuming and expensive. Several
14
days are required for a definitive identification. This 
long period of time makes culture and follow-up bacteriology 
impractical for both clinical diagnosis and environmental 
screening.
Two current approaches for rapid identification of a 
microorganism are DNA probes and antigen detection. Both 
techniques are specific and sensitive. At the present time 
two gene probes have been constructed to detect V. 
vulnificus: one for the toxin gene and a second for the 
chitinase gene. The toxin gene shows the most promise as a 
diagnostic probe (Wright et al., 1985; Wortman et al.,
1986). Utilization of DNA probes in the clinical 
microbiology laboratory requires skilled personnel and a 
well equipped laboratory. Some of the problems encountered 
with the utilization of DNA probes can be eliminated by 
using monoclonal antibody based antigen detection reagents.
Monoclonal antibody based assays such a enzyme 
immunoassay (EIA), Latex or Co-agglutination can be 
completed within one hour. Equipment needed to perform 
these assays is minimal and most laboratory technicians are 
familiar with these techniques.
When designing prototype rapid identification reagents 
several questions must be asked. First, is there a "non- 
pathogenic" or "avirulent" biotype of this organism in the 
environment? A practical procedure must differentiate non­
pathogens from the pathogens. Second, is there a
characteristic that is exclusively associated with 
virulence? An "in vitro" correlate of virulence may be a 
morphological, biochemical or antigenic difference between 
the virulent and avirulent organisms. A final question that 
must be answered. What is the minimal lethal dose of V. 
vulnificus for humans? The answer to this question may 
never be known, but, it is possible to assess the virulence 
of this organism based on animal models.
This dissertation will be divided into three chapters. 
The first chapter will outline the characterization of the 
Louisiana V. vulnificus isolates used in this study. The 
second chapter will deal with the production of vaccines to 
produce high titered polyclonal antisera for use in an LPS 
based serotyping scheme for V. vulnificus. The third 
chapter will cover the affinity purification of polyclonal 
antisera and the development of monoclonal antibodies for 
V. vulnificus serovars.
Chapter I Characterization of Vibrio vulnificus 
Isolates from Louisiana
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Abstract
Twenty-three different V. vulnificus strains isolated 
in Louisiana were examined to determine if these strains 
resembled phenotypically the ATCC type strain for this 
species. The human and environmental isolates were screened 
for reactions on Kliger's Iron agar (KIA), Lysine Iron Agar 
(LIA), and TCBS agar. These same isolates were then 
screened for hemolysin production, lethality for Balb/c mice 
and clearance from the peripheral blood stream of the 
rabbit. The Louisiana isolates were hemolytic, lethal for 
Balb/c mice and were all rapidly cleared from the blood 
stream. Opaque and translucent phenotypes of five V. 
vulnificus were isolated. Only the opaque to translucent 
phenotype change occurred. These phenotypic variants were 
then screened for plasmid content. None of these strains 
were found to carry a plasmid. This suggests that the 
mechanism for opaque to translucent switching is genomic.
The V. vulnificus isolates were tested to determine the 
bactericidal effect of apo-lactoferrin. All of the V. 
vulnificus isolates screened showed resistance to apo- 
lactoferrin.
17
Introduction
Vibrio vulnificus. a recent addition to the genus 
Vibrio, has been recognized as a human pathogen for only a 
decade, there are several questions relating to this 
organism that remain to be answered. First, does each 
Louisiana V. vulnificus isolate resemble phenotypically the 
ATCC type strain # 27562? Second, are there differences 
between human and environmental isolates? Finally, is 
there a non-pathogenic or avirulent phenotype of V. 
vulnificus?
Twenty-three Louisiana isolates were compared with the 
ATCC type strain and isolate E4125 (Centers for Disease 
Control, Atlanta, Ga.) by a minimum number of biochemical 
tests to determine that each isolate was, in fact, V. 
vulnificus. In addition, each isolate was examined for 
hemolysin production, mouse lethality and, clearance from 
the peripheral blood stream of the rabbit.
These preliminary studies provided some insight into 
the type of disease produced and confirmed that the 
Louisiana isolates were pathogenic. From this point the 
research branched off in two different directions. First 
the production of a capsular or slime layer was examined. 
Isolates were screened for capsule production (opaque 
colonies) or lack of capsule production (translucent
18
colonies). After opaque and translucent colony types had 
been isolated, each phenotype was screened for plasmid 
production. Finally, the sensitivity of Vibrio vulnificus 
isolates to the bactericidal action of apo-lactoferrin was 
tested.
Materials and Methods
Bacterial Strains. Twenty-three Louisiana V. vulnificus. 
isolated from humans and the environment were provided by 
the Louisiana Department of Health and Human Resources, 
Division of Laboratories (Table 1). Vibrio vulnificus ATCC 
#27562 (American Type Culture Collection, Rockville, Md.) 
and isolate E4125 (Dr. R.E. Weaver and Dr. D. G. Hollis of 
the Centers for Disease Control, Atlanta, Ga.) were used as 
the prototype strains (Table 2).
Culture Identification and Maintenance. Bacterial cells 
were grown at 37° C on alkaline peptone agar pH 8.0 (1% 
peptone, 2% NaCl, 1.5% agar, 0.2% yeast extract). Each 
isolate was stored on maintenance media (8 grams Bacto 
Tryptone, 5 grams NaCl, 4 grams Nutrient Broth, 4 grams 
agar, qs to 1 liter with dH20) . To insure consistency, 
bacterial strains were maintained in a frozen state in 15% 
glycerol tryptic soy broth as well as on maintenance media. 
Each strain was inoculated on Kigler's Iron agar (KIA), 
Lysine Iron Agar (LIA) (supplemented to 2% NaCl) and 
Thiosulfate-Citrate-Bile-Salt agar (TCBS) to insure that 
pure cultures were maintained (Table 3).
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TABLE 2. Louisiana Vibrio vulnificus isolates, patient 
information, and strain designations. All isolates were 
received from the Louisiana Department of Health and Human 
Services Division of Laboratories.
Isolate Sp. Dis Outcome Seafood Contact Age Sex Hist.
Vv 846 c WI Lived Raw Oysters* 7 M None
VvlOOO s D Lived Unknown 69 M CA,Ulcer
VvlOOl B PS Died Raw Oyster, 
Crayfish
41 M Cirrhosis 
Ulcer 
Ren.Dis.
W1002 B PS Lived Unknown 55 M Cirrhosis
Diabetic
Vvl003 B WI Lived Crab Puncture 64 M Kid. Inf.
Vvl004 S D Lived Raw Oysters 53 M Ulcer
Vvl005 B PS Died Raw Oysters 73 M Leukemia
VV1006 B PS Lived Raw Oysters 52 F Alcoholic
VV1007 B PS Died Raw Oysters, 
Crab
69 F Ulcer 
Ren. Dis. 
Diabetic
Vvl008 S D Lived Raw Oysters 28 M Chronic
Indigest
VV1009 B PS Died Raw Oysters, 
Crab
58 M Cancer, 
Ren. Dis.
VvlOlO B PS Died Unknown 83 M Cirrhosis
Cancer,
Ulcer
Vvl012 P PS Died Raw Oysters 60 M Ren. Dis. 
HeartDis
Vvl013 B PS 7 7 7 M 7
VV1014 7 7 7 7 7 7 7
Vvl015 7 WI 7 7 7 7 7
Vvl355 B WI Lived 7 67 M Alcoholic
VV1365 W WI Lived 7 70 M Cancer
HeartDis
Vvl456 W WI Lived 7 75 M Chronic
Pulm.Dis
VV2098 7 7 7 7 7 7 7
B= Blood C=Cornea
S= Stool D= Diarrhea
P=Peritoneal fluid Sp=Specimen type
PS= Primary septicemia Dis= Disease
WI= Wound Infection 
? = Not Available
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Freezing Bacterial Cultures. Bacteria were harvested from 
the surface of an alkaline peptone slant in 3.0 ml of 
cryostorage solution (Tryptic Soy Broth, 5% glycerol). One- 
half ml of bacterial suspension was placed in cryotube 
(Nalge, A Division of Sybron Corporation, Rochester, N.Y.). 
Tubes were immediately stored at -70° C. The frozen stock 
cultures of V. vulnificus isolates were collected between 
1977 and 1982. These organisms have been frozen and thawed 
as well as being held on maintenance media for several years 
prior to being frozen during the summer of 1988, and may 
differ from the original isolate recovered from the clinical 
or environmental specimen.
Hemolysis Assays. The ability of V. vulnificus to lyse both 
rabbit and mouse erythrocytes was determined on blood agar 
plates. Blood agar was prepared by adding a 5% suspension 
of donor erythrocytes to alkaline peptone agar, pH 7.2. The 
blood was obtained aseptically from either Balb/c mice or 
New Zealand White rabbits. Each plate was then divided into 
quadrants, and each isolate tested was struck onto one 
quadrant on each of three separate plates. The results were 
recorded as a-hemolytic if partial hemolysis was observed, 
B-hemolytic if complete hemolysis was observed, and r -  
hemolytic if no hemolysis was seen (Table 4).
Mouse Lethality. The lethality of V. vulnificus for mice 
was determined by intraperitoneal injection (I.P.) of a
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standardized live vaccine. Since a baseline lethal dose 
value was not available, two pilot studies were done. In the 
first study, for each of the five isolates tested, a single 
mouse was injected I.P. with 5 x 109 live organisms. The 
animals were then observed every two hours. In the second 
pilot study seven strains were tested. This second 
experiment used five mice for each strain tested. Each 
mouse was injected I.P. with 1 x 108 live V. vulnificus 
cells. At this point, enough preliminary data was available 
to do a quantitative LD50.
Determination of LD50. The protocol for the determination of 
an LD50 for V. vulnificus, based on the method of Reed and 
Muench (1938), was submitted to the animal care and use 
committee. The animal care and use committee rejected the 
protocol, and no reason for this rejection was communicated 
to the author. Because the above cited protocol is the only 
long standing, universally accepted method for determining 
fifty per cent endpoints available and the fact that the 
committee wasn't forthcoming with any specific complaints, 
this experiment was abandoned.
Translucent and Qpaoue Strain Variation. Each V. vulnificus 
strain used in this study had been cultured continuously on 
maintenance medium since 1982. It was not unusual to see 
various sizes of colonies in a pure culture. All V. 
vulnificus strains in the collection were subcultured on 
alkaline peptone agar, using an oblique light source.
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Opaque and translucent colony types were separated where 
possible. Both translucent and opaque strains were isolated 
from W 8 4 6 , W1005, W1007, Vvl008, and W1013.
Capsular Phenotype Switching. To determine if opaque to 
translucent switching was bidirectional or unidirectional a 
single colony of each opaque and each translucent phenotype 
was inoculated into alkaline peptone broth. These organisms 
were grown at 37° C overnight and a 10 ul was transferred to 
a second broth. The organisms were serially passed from 
tube to tube for five days, then plate counts were done. 
Plasmid screening. The translucent and opaque phenotypes of 
Vvl005, Vvl007, Vvl008, and Vvl013 were screened for 
plasmids. DNA preparations were separated by electro­
phoresis on 0.7% agarose gels, stained with ethidium 
bromide, and observed with 360 nm U.V. light (Birnboim and 
Doly 1980).
Clearance of opaoue and translucent variants in rabbits.
New Zealand White rabbits were immunized with 109 live V. 
vulnificus via intravenous injection in the marginal ear 
vein. Blood was drawn immediately from the central artery 
of the opposite ear as a time zero bacterial plate count. 
Dilutions of blood samples obtained at 10, 20, 30, 40, 50, 
and 60 minutes post injection were plated on alkaline 
peptone agar.
Lactoferrin Susceptibility. The susceptibility of V. 
vulnificus to the bactericidal action of human lactoferrin
25
was determined by exposing V. vulnificus cells to apo- 
lactoferrin (iron free lactoferrin). Five mg of human apo- 
lactoferrin (Sigma chemical Co., ST. Louis, Mo.) was 
dissolved in 2 ml acetate-EDTA buffer containing 0.2 M 
NaH2P04, 0.04 M EDTA, 0.2 M acetic acid, 0.2 M sodium 
acetate, pH 4.0, and dialyzed against six changes of 
acetate-EDTA buffer to remove residual iron, followed by 
dialysis against two changes of double glass distilled water 
to remove the acetate-EDTA buffer. The apo-lactoferrin 
solution was standardized to 2.5 mg per ml and stored at 
-70° C. Vibrio vulnificus cells were harvested in 2 ml of 
0.067 M PBS from the surface of alkaline peptone agar 
slants. The cell suspension was added dropwise to 25 ml 
alkaline peptone broth, in a side arm flask, until the 
turbidity reached 36 Klett units (3.0 x 108 cells per ml). 
The flask was incubated at 37° C with shaking until the 
turbidity reached 75 Klett units. Cells were sedimented at 
2,800 x g, for 10 minutes and resuspended in 0.067 M PBS to 
36 Klett units ( 3.0 x 108 cells per ml). To a 13 x 100 mm 
tube, 0 . 1  ml of cell suspension was added, 0 . 1  ml of apo- 
lactoferrin, and 0.9 ml alkaline peptone broth pH 7.2. The 
negative control tube received the Vibrio suspension but, 
did not receive apo-lactoferrin. A time zero sample (0.10 
ml) was removed and immediately diluted in 0.067 M PBS for 
aerobic plate count. The tubes were then incubated at 37° C 
for four hours, at which time a second aliquot of the
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reaction mixture was removed, and plates counts were done 
(Table 8 ).
Results and Discussion
Twenty-three V. vulnificus isolates were examined to 
determine if these strains phenotypically resembled the ATCC 
type strain 27562 and CDC isolate E4125. The disease caused 
by the twenty human isolates was what was to be expected 
from a review of the literature (Thorsteinsson et al. 1974; 
Blake et al. 1979; Blake et al. 1980; Bonner et al. 1983). 
The age and sex of the victims is known for fifteen of the 
isolates, thirteen of the fifteen victims were male (8 6 %) 
and had an average age of 61 years (Table 2). There was a 
history of consumption of raw seafood in thirteen of the 
sixteen (81%) cases where information was available and all 
of the patients had an underlying disease such as cirrhosis 
or ulcers. In this small sample there was a 38% mortality 
rate (6/16).
Each V. vulnificus isolate was inoculated onto 
Kligler's Iron Agar (KIA), Lysine Iron Agar (LIA), and TCBS 
agar to insure that pure cultures were maintained (Table 3). 
Since these isolates had been exhaustively reidentified many 
times in our laboratory, they were not subjected to 
additional testing.
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TABLE 3. Biochemical characteristics used to screen Vibrio 
vulnificus isolates. Media adjusted to attain a 2% NaCl 
concentration. Reaction read at 24 h.
TCBS
Isolate Sucrose KIA LIA Froz«
Vv 846H 0 K/A° K/K° +
VvlOOOH 0 K/A° K/K" +
W 1 0 0 1 H 0 K/A° K/K° +
W 1 0 0 2 H 0 K/A° K/K° +
W 1 0 0 3 H + K/A° K/K° +
W 1 0 0 4 H 0 K/A" K/K° +
W 1 0 0 5 H 0 K/A° K/K° +
W 1005T 0 K/A° K/K° +
W 1 0 0 5 O 0 K/A” K/K” +
W 1 0 0 6 H 0 A/A” K/K° +
W 1 0 0 7 H 0 K/A” K/K° +
W 1 0 0 7 T 0 K/A° K/K° +
W 1 0 0 7 0 0 K/A” K/K” +
W 1 0 0 8 H 0 K/A” K/K” +
VV1008T 0 K/A” K/K° +
W 10080 0 K/A” K/K” +
W 1 0 0 9 H 0 K/A” K/K° +
VvlOlOH 0 K/A° K/K° +
W 1 0 1 2 H 0 K/A” K/K” +
W 1013H + K/A" K/K° +
W 1013T 0 K/A” K/K° +
W 10130 + K/A” K/K° +
W 1 0 1 4 H 0 K/A' K/K” +
VV1015H 0 K/A” K/K° +
W 1 3 5 5 H 0 K/A° K/K° +
W 1 3 6 5 H 0 K/A” K/K° +
W 1 4 5 6 H 0 K/A” K/K° +
W 2 0 9 8 H 0 K/A” K/K° +
W E4125 0 K/A” K/K° +
WATCC27562 0 K/A” K/K° +
W 1 2 5 E 0 K/A° K/K° +
W 1 3 7 E 0 K/A” K/K° +
W 1 5 8 E 0 K/A” K/K° +
VCVCE271 + K/A” K/A° 0
H= Human isolate T= Translucent 0= Opaque
E= Environmental isolate 
Vv= V. vulnificus 
Vc= V. cholerae (control) 
K= Alkaline]
A= Acid 
°= No Gas
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To determine whether a non-pathogenic or virulent V. 
vulnificus strains existed, we chose to screen our isolates 
for hemolysin production and pathogenicity in mice. One of 
the classic characteristics of a virulent pathogen is the 
ability to produce hemolysins. All of the Louisiana V. 
vulnificus isolates were found to hemolyze mouse blood 
within forty-eight hours, and ten of thirteen (77%) were 
hemolytic on rabbit blood agar (Table 4). These results 
agree with the reports in the literature (Johnson and Calia 
1981).
Each of the twenty human V. vulnificus isolates and 
each of the environmental isolates was tested for 
pathogenicity using Balb/c mice. In the first experiment, a 
single mouse was injected intraperitoneally with 5 x 109 V. 
vulnificus cells. Thirteen human isolates and 7 
environmental V. vulnificus isolates were tested (Table 5). 
Two of the human isolates (W1008, W1009) were non-lethal 
for Balb/c mice at 5 x 109 cells, all the remaining strains 
18/20 (90%) tested were lethal within twenty-four hours. In 
a second experiment, 1 x 10® V. vulnificus cells were 
injected intraperitoneally into Balb/c mice. This lower 
cell inoculum was chosen so that an infection more closely 
resembling a naturally occurring infection would result. 
Seven V. vulnificus human isolates were tested at 1 x 108 
cells per mouse. Two strains were found to be more rapidly
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TABLE 4. Hemolytic patterns for representative Vibrio 
vulnificus human isolates observed on rabbit blood agar 
(rRBC) and mouse blood agar (mRBC) plates following 24 and 
48 h of incubation.
24 hrs. 48hrs •
Isolate mRBC rRBC mRBC rRBC
VvlOOOH r B B Bw
W 1002H B Bw B Bw
W 1 0 0 3 H B B fi B
W1004H r Bw B Bw
W 1005H B B B B
W 1006H r r B r
VV1007H B Bw B Bw
VV1008H B Bw B Bw
W 1 0 0 9 H r r B r
W 1010H r r B r
W 1012H B r B Bw
W 1013H B r B Bw
W 1015H B Bw B B
B= Beta hemolytic 
r= Gamma hemolytic 
w= weakly hemolytic 
H= Human isolate
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lethal (W1002, Vvl012) , killing the mice within four hours, 
and two strains were found to be less lethal (Vvl008, 
WE4125) , allowing the mice to survive beyond twenty-four 
hours, with the remaining three strains falling between 
these two extremes (Table 6 ). The next logical experiment 
would be to take a highly virulent strain (Vvl002) and a 
less virulent strain (Vvl008) and determine the LD50, 
however, as noted previously, we were not allowed to conduct 
that experiment. Using the qualitative information that was 
available from the lethality studies we decided to 
investigate the contribution of cell surface components to 
virulence.
This direction was taken because Bowdre et al. (1981) 
have shown that V. vulnificus cells implanted subcutaneously 
within a diffusion chamber could survive several weeks in 
vivo without producing a lesion. The membrane (0.2 urn) on 
this chamber prevented direct contact of the organism with 
the host but, would allow for the free diffusion of 
bacterial products. Since presumably the V. vulnificus 
toxin (M.W. 56Kd) would be able to diffuse into the
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TABLE 5. The virulence of selected environmental and human 
V. vulnificus isolates for Balb/c mice injected with 5 x 109 
cells by the intraperitoneal route.
Isolates 2h 4h 6 h 8 h lOh 12h 24h 36h 48h
VvlOOOH ................................D
W 1 0 0 2 H .... D°
W 1003H ................................D
VV1004H ................................D
VV1005H  D
W 1 006H ........................... D
W 1 0 0 7 H .... D
W1008H ........................................... Sb
W 1 009H ........................................... S
VvlOlOH ................................ D
VV1012H  D
VV1013H ................................ D
W 1 0 1 5 H .... D
W 1 1 8 E  ................................ D
W 1 2 5 E  ................................ D
VV133E ................................ D
W 1 3 7 E  ........................... D
W 1 4 0 E  ................................ D
W 1 4 2 E  ................................ D
W 1 4 9 E  ................................ D
Control ............................................ S
aD= Deceased 
bS= Survived
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TABLE 6 . Time course mortality study of seven human V. 
vulnificus isolates. Five mice were used for each strain 
tested. Mice were injected intraperitoneally with 1 x 108 
live cells at time zero (00.) and observed at 30 minute 
intervals for eighteen hours.
Time Mice Remaining Alive
Hours W1002 W 1 0 0 5 Vvl007 W1008 VV1012 Vvl015 VvE4125
. 0 0 5 5 5 5 5 5 5
.50
1 . 0 0 3
1.50 2
2 . 0 0 0
2.50
3:00 4
3.50 2
4.00
4.50 1
5.00
5.50 4
6 . 0 0 2
6.50 4
7.00
7.50 4 1
8 . 0 0 3 1
18.0 0 0 0 4 0 0 5
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interstitial fluid, one would expect at least some local 
edema. The toxin produced by V*. vulnificus was first 
described by Kreger and Lockwood (1981). This toxin 
wasisolated from culture filtrates and was found to be 
cytotoxic, hemolytic, lethal for mice, and to increase the 
vascular permeability in guinea pig skin (Gray and Kreger 
1985). Due to the necessity for direct contact between the 
bacterium and the host for disease production, cell surface 
characteristics were involved in V. vulnificus disease.
The search for a cell surface component that was 
associated with virulence should to be directed at molecules 
exposed on the cells surface such as outer membrane proteins 
(OMP's), lipopolysaccharide (LPS), and capsule.
The lipopolysaccharide antigen profile of V. cholerae 
has been very useful in both diagnostic and epidemiological 
studies. The previous success with LPS serotyping of V. 
cholerae made the LPS an obvious first choice for a 
virulence marker. The development of an LPS serotyping 
scheme for V. vulnificus will be covered in chapters two and 
three.
Many strains of JL vulnificus produce a layer of 
polysaccharide slime or capsular material. Viewing colonies 
grown on clear media with an oblique light source, it is 
possible to distinguish both opaque and translucent colony 
types (Amako et al. 1984; Yoshida et al. 1985). Yoshida et
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al. have shown that the LD50 for mice and the ability to 
resist the bactericidal action of serum varies depending 
upon the opacity of the strain. The opaque strains show an 
decreased LDS0 and an increased resistance to the 
bactericidal activity of serum as compared to the 
translucent strains. Because of the antiphagocytic 
properties of bacterial capsules in general and the reports 
that V^ . vulnificus is less susceptible to phagocytosis than 
other vibrio pathogens, this capsular material seems to be 
important (Kreger et al. 1981; Tamplin et al. 1983; Tamplin 
et al. 1985). It has also been reported that capsular 
materials may be useful as vaccines and that passively 
transferred anticapsular antibody may raise the LD50 by up 
to 40-fold (Cryz et al. 1984; Cryz et al. 1985).
Opaque (encapsulated) and translucent (non­
encapsulated) phenotypes of five Louisiana V. vulnificus 
have been isolated (Figure 1). Starting with "pure" 
cultures of opaque cells and passing the culture from broth 
to broth for five days a mixed culture of both opaque and 
translucent cells was recovered. If the starting culture 
was a translucent phenotype, only translucent cells were 
recovered. The opaque to translucent phenotype switch 
occurred rapidly, however, the translucent to opaque switch 
was not observed (Table 7). The actual rate of this 
switching is difficult to determine because in addition to 
the translucent and opaque phenotypes there are a large
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number of sectored colonies containing both phenotypes (Fig. 
1). These colonies show a sector of translucent and a 
sector of opaque growth. In the sectored colonies, the 
opaque variant accounts for the majority of the colony with 
< 25% being translucent. Some opaque colonies have more 
than one translucent sector. There have been no translucent
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TABLE 7. Frequency of switching from opaque to translucent 
and translucent to opaque phenotypes of Vibrio vulnificus. 
Pure culture of opaque or translucent that had been passed 
daily for five days from broth to broth. Results are mean 
values of three experiments.
Colony Types
Original Strain Opaque(%) Translucent(%)
VV1005-0 2 X 107 (17.4) 9.5 X 107 (82.6)
W1005-T None 2.5 x 107 (100)
W1008-0 4.5 x 107 (56.2) 3.5 X 107 (43.8)
W1008-T None 4.0 x 107 (100)
W1013-0 5.5 x 107 (64.7) 3.0 x 107 (35.3)
VV1013-T None 1 . 0  x 1 0 8 (1 0 0 )
38
Figure 1. Translucent and opaque phenotypes of V. 
vulnificus strain Vvl005H on alkaline peptone agar pH 8.0. 
Note the numerous sectored opaque colonies. No sectoring is 
observed with the translucent phenotype.
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colonies that have opaque sectors observed. Due to 
sectoring of the colonies an accurate conversion can not be 
established by simple plate count. Using electron 
microscope studies, Yoshida et al. (1985) estimated the 
opaque to translucent switching rate at « 2 x 1 0 '4, they 
also estimated a translucent to opaque switching rate at <
1 . 8  x 1 0 '4.
Some strains, such as ATCC 27562, appear to be light 
variants. This may be a laboratory artifact. In the 
selection of colonies to be placed in maintenance medium, a 
single translucent variant may have been selected for 
transfer which would have eliminated the opaque variants. 
These cultures may then be carried as translucent variants.
Opaque and translucent phenotypes were screened for 
plasmids because loss of a plasmid would conveniently 
explain a unidirectional phenotype switch. No plasmids were 
found in any of the organisms tested. Studies by Davidson 
and Oliver (1986) found plasmids in only 12% of V. 
vulnificus isolates tested, and these plasmids were found to 
be a various molecular weights, none of the human isolates 
contained a plasmid.
The final study undertaken has been the testing of V. 
vulnificus sensitivity to lactoferrin. Lactoferrin is 
produced in neutrophils and in the acinar epithelial cells 
that line mucous membranes. Lactoferrin is found in mucous 
secretions, and milk and has been shown to have a
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bacteriostatic effect (Bullen et al. 1978; Weinberg 1978). 
This bacteriostatic effect can be abolished by adding enough 
iron to the system to saturate lactoferrin's iron binding 
capacity. It was therefore thought that lactoferrin 
functioned to chelate iron thereby making it unavailable for 
the bacteria. The addition of iron compounds above levels 
that can be bound by serum proteins is also detrimental to 
neutrophil function and lowers the antibacterial effect of 
human plasma (Ward et al. 1986).
A bactericidal activity for human lactoferrin was 
first demonstrated by Arnold et al. in 1977. Lactoferrin 
has been found to be bactericidal for a wide variety of 
microorganisms (Arnold et al. 1980; Mickelsen et al. 1982; 
Bortner et al. 1986). Some of these organisms have been 
found to able to obtain iron from lactoferrin (Mickelsen et 
al. 1982).
The sensitivity of Vs. vulnificus to lactoferrin was 
tested by exposing the organism to Apo-lactoferrin (iron 
free) and doing plate counts over a four hour period. The 
results indicate that the nine V^ . vulnificus strains tested 
were insensitive to the bactericidal activity of 
lactoferrin, which would make these strains less susceptible 
to polymorphonuclear leucocytes (PMN) and secretory immunity 
(Table 8 ). If lactoferrin caused no change in bacterial 
growth, both test and control cultures would be expected to 
grow at the same rate, one would expect a growth.index of
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TABLE 8 . The sensitivity of Vibrio vulnificus isolates to 
the bactericidal effects of apo-lactoferrin. Log phase V. 
vulnificus cells « 105 cells per ml. Test tubes received 250 
ug per ml apo-lactoferrin. Control tube received broth 
only. All plate counts done in triplicate.
Organism Control Test (w/LF) G. I . a
VvlOOO T 2.4 X 1 0 6 1.7 X 1 0 6 .570
t4 3.5 X 1 0 7 1.5 X 1 0 7
W 1 0 0 2 T_ 5.6 X 1 0 7 3.4 X 1 0 7 2 . 6o
T4 3.4 X 1 0 8 4.9 X 1 0 8
Vvl003 T„ 4.0 X 1 0 4 3.9 X 1 0 4
o•oo
T4 8 . 0 X 1 0 7 1.9 X 1 0 4
W A T C C  27562 Tn 7.6 X 1 0 4 1.9 X 1 0 4 .85o
t4 1 . 6 X 1 0 5 3.7 X 1 0 4
WE4125 4.1 X 1 0 3 5.0 X 1 0 3
o•010
t4 4.0 X 1 0 5 1 . 2 X 1 0 3
W1005-0 Tn 1.5 X
inoH
3.0 X 1 0 5 1.90
T4 1.3 X 1 0 6 4.7 X 1 0 6
VV1005-T T„ 1.3 X 1 0 5 1.3 X 1 0 5 . 0 10
T4 3.0 X 1 0 6 1.7 X 1 0 5
W1008-0 1.5 X 1 0 3 2.5 X 1 0 3 . 2 00
t4 3.0 X 1 0 5 1 . 0 X 1 0 5
W1008-T T. 2.5 X 1 0 3 2 . 0 X 1 0 3 o • oo
t4 1 . 0 X 1 0 5 2 . 0 X 1 0 3
V. cholerae T0 2 . 1 X 1 0 3 1.5 X 1 0 3 1.09
(1403) t4 4.7 X 1 0 6 3.6 X 1 0 6
V. cholerae T. 9.5 X 1 0 7 7.8 X 1 0 7 .63o
t4 9.7 X 1 0 8 5.3 X 1 0 8
aG.I.= % increase in cell number w/o LF 
% increase in cell number w/ LF
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1.0 over the four hour test period. A bactericidal effect 
should have caused a negative growth index. Of nine strains 
tested three showed some inhibition, and six strains showed 
no inhibition. Both W1005-T and W1008-T showed less 
growth than did their opaque counterparts (Table 8 ). The 
bactericidal effect of lactoferrin can usually reduce the 
numbers of organisms by several thousand fold. It therefore 
seems unlikely that the small effect seen here is due to 
this bactericidal effect.
The major questions to be addressed, with regards to 
V. vulnificus are:
1. Are there LPS serotypes?
2. If there are LPS serotypes can they be used as
virulence markers, i.e. in vitro correlates of 
virulence?
3. Is there a different unique capsular polysaccharide 
or is the difference between opaque and 
translucent colonies simply a smooth and rough LPS 
phenotype?
4. Does this proposed capsular material mask or hide
the LPS epitopes from the immune system?
5. Can a unique capsular polysaccharide be isolated and
used to serotype V. vulnificus?
Chapters two and three of the dissertation address the first 
four questions.
Chapter II Production of Vibrio vulnificus Serovar- 
Specific Polyclonal Antisera
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Abstract
Immunization of rabbits with V. vulnificus produces a 
low LPS or O antigen antibody titer as compared with titers 
seen when other members of the genus Vibrio, such as V. 
cholerae. are used as an immunogen. Vaccines were produced 
using heat killed cells, formalinized cells, and acetone 
dried cell homogenates. These preparations did not cause a 
significant increase in the antibody titer. Since the 
response to whole cell vaccine was uniformly poor, the use 
of polysaccharide-protein carrier conjugates was tested as a 
way to increase the antibody titer. LPS was extracted from 
V. vulnificus and purified by both enzyme treatment and 
differential centrifugation. The poly-saccharide was then 
removed from the LPS by alkaline hydrolysis and differential 
centrifugation to pellet the lipid moiety. Two methods of 
conjugation were used. The first employed cyanogen bromide 
as the linking agent, the second used benzoquinone as the 
linking agent. These PS-carrier conjugates did not enhance 
the production of anti-V. vulnificus antibody.
These results demonstrate that V. vulnificus LPS is 
less iitimunogenic than V. cholerae LPS.
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Introduction
The lipopolysaccharide associated O-antigen expressed 
by Vibrio cholerae has proved to be an invaluable tool in 
ecologic and epidemiologic studies. The O-antigen typing of 
V. cholerae into the 01 and the non-01 groups also provides 
a basis for the distinction between classical Asiatic 
cholera caused by V. cholerae serovars Inaba and Ogawa (O- 
group 1 ) and the usually less severe gastroenteritis caused 
by the non-0 1 's.
Considering the success of O-serotyping as applied to 
V. cholerae it was practical to extend this approach to 
other Vibrio species. The first attempt to develop an 0- 
serological typing scheme for V. vulnificus was reported by 
Shimada and Sakazaki (1984). In this scheme, heat killed 
organisms were used to produce polyclonal antisera in 
rabbits. In the test system, whole cells that had been 
heated to 100° C for two hours and washed twice were mixed 
with antisera in tubes. Cross-reactivity between many of 
the strains tested could be removed by absorption of the 
antisera with a "rough" strain. Seven O-serological 
varieties (serovars) were identified among 70 V. vulnificus 
isolates examined by Shimada and Sakazaki (1984).
Shimada also reported that many of the organisms they 
examined were inagglutinable in the living state. This 
observation lead them to conclude that a heat-labile antigen
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was present that masked the O-antigens.
The typing scheme proposed by Shimada and Sakazaki is 
based upon whole-cell vaccine and polyclonal antisera. 
Although these techniques provide much valuable information, 
a more precise typing scheme based on chemically defined 
antigens is desirable. A serological typing scheme based on 
specific LPS antigens would eliminate non-specific results 
and might provide for more accurate studies of serological 
variation.
Two different problems have plagued us during the 
course of these studies. The first was our inability to 
raise high titered antisera to V. vulnificus LPS. The 
second recurring problem was the cross reactivity observed 
between V. vulnificus isolates.
Different approaches were investigated to prepare 
immunogens for the immunization of rabbits. Heat killed, 
formalin killed, and acetone dried whole cell vaccines were 
used. Polysaccharide-carrier conjugates were prepared using 
the cyanogen bromide procedure described by Adams and 
Siebeling (1984), and using the benzoquinone procedure 
described by Brandt et al. (1975). None of these techniques 
produced a significant increase in the anti-LPS titer.
Materials and Methods
Whole Cell Vaccines. Whole cell vaccines were produced by 
growing V. vulnificus isolates on alkaline peptone agar (1% 
peptone, 2% NaCl, 0.2% yeast extract, 1.5% agar, pH 7.3).
The cells were harvested with 0.15 M saline with 0.3% 
formaldehyde (formalinized cells) or in 0.15 M saline. 
Formalin killed vaccine cells, harvested with formaldehyde- 
saline, incubated at 4°-8° C for 48 hours and then 
subcultured to insure that no viable organisms remained. 
Heat-killed whole cell vaccines were prepared by incubation 
of cells, harvested in saline, in a boiling water bath for 1 
hour. The heat-killed whole-cell vaccines were cooled and 
subcultured to thioglycolate broth to insure that no viable 
cells remained. The formalin-killed and heat-killed whole 
cell vaccines were standardized to 1 x 1 0 10 organisms per ml 
(380 Klett units at 520 NM). New Zealand white rabbits were 
immunized intravenously with 1 ml of the standardized 
vaccine every other day for three weeks.
Acetone Dried Cell Vaccine. Selected V. vulnificus strains 
were harvested in saline, washed once with saline, and 
resuspended in 1 0 ml of acetone and stored at room 
temperature overnight. The cells were pelleted and allowed 
to dry completely (2-3 days). The desiccated cell mass was 
ground into a fine powder with mortar and pestle. The 
acetone-dried cell powder was suspended in 0.067 M PBS at a
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were immunized intravenously over a three week period. A 
total of 8.5 ml of vaccine was administered over the 
immunization period.
LPS Preparation. Lipopolysaccharide (LPS) used in this 
study was extracted from V. vulnificus isolates using the 
hot phenol-water technique of Westphal and Jann (1965).
LPS detoxification. The LPS consists of both a lipid and a 
polysaccharide moiety. To produce the protein carrier 
conjugates, only the polysaccharide (PS) portion was needed. 
The lipids were removed by alkaline hydrolysis. Five 
milligrams of LPS was suspended in 5 ml of distilled water, 
0.1 ml of 1.0 N NaOH was added, and the mixture was 
incubated at 37° C for 5 hrs. Following incubation the 
hydrolysate was dialyzed against 0.067 M PBS to neutralize 
the NaOH. The lipid was pelleted by centrifugation at
100,000 x g for 3 h. The supernate was quantitated for 
carbohydrate and adjusted to 1 mg carbohydrate per ml. 
Preparation of Polvsaccharide-Carrier Conjugates. Two 
methods were used to conjugate PS to bovine gamma globulin 
(BGG). The first method employed CNBr to activate the PS 
and the second used Benzoquinone.
CnBr Conjugation. The CNBr coupled reagent was prepared 
using the procedure of Adams and Siebeling (1984). 
Polysaccharide was activated by dissolving 10 mg PS in 2 ml 
0.15 M H5BO3-O.5 M NaCl pH 8 .6 . To this solution 7 mg CNBr 
was added and the mixture was stirred at room temperature at
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an alkaline pH for 15 minutes. Ten ml of a 1% solution of 
BGG (in borate-saline buffer) was added and the mixture was 
stirred overnight at 4° C. The PS-CNBr-BGG conjugate was 
dialyzed against saline for 24 hours and the volume was 
reduced to 5 ml using aquacide (Calbiochem, San Diego, Ca.). 
Benzocruinone conjugation. A PS-benzoquinone moiety was 
prepared by utilizing a modification of the coupling 
technique described by Brandt et al. (1975). Ten milligrams 
of detoxified LPS (PS only) was dissolved in 5 ml of 0.067 M 
PBS pH 7.3. With constant stirring, 6 mg of freshly 
sublimed benzoquinone was added (0.2 ml of a 30 mg per ml 
stock solution in absolute ethanol). The mixture was 
incubated at 4° C for 1 hour in the dark with constant 
gentle stirring. The benzoquinone activated PS was 
precipitated by the addition of 20 ml of cold (-20° C) 
absolute ethanol. Ten milliliters of a 0.1% BGG solution (1 
mg per ml in PBS) was added to the activated PS. This 
mixture was stirred gently, in the dark, at 4° C for 
eighteen hours. The PS-Benzoquinone-BGG conjugate was 
dialyzed against PBS and the volume was reduced to 5 ml 
using aquacide (Calbiochem, San Diego, Ca.).
Rabbits were immunized subcutaneously with 2.5 ml of 
the PS-BGG conjugates emulsified in an equal volume of 
Freund's complete adjuvant. Twenty-one days later the 
rabbits were boosted with 2.5 ml of conjugate emulsified 
with Freund's incomplete antigen.
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O-Antiaen Tube Agglutination. Live V. vulnificus cells 
harvested from the surface of alkaline peptone slants in 
0.15 M NaCl were washed two times and standardized to 1 x 
109 cells per ml. Serial two-fold dilutions of immune sera 
were made in 0.5 ml volumes in saline. Prebleed sera and 
normal rabbit sera were used as control sera. To each tube, 
0.5 ml of standardized bacterial suspension was added. The 
contents of each tube was vortexed to insure complete 
mixing, incubated at 40° C for two hours and examined for 
evidence of discernable agglutination. The tubes were 
reincubated at 4° C for 24 h and examined again for 
agglutination.
Passive Hemagglutination. Blood drawn from New Zealand 
white rabbits was suspended in an equal volume with 
Alsever's citrate-saline solution and held at least three 
days at 4° C before use. The RBCs were washed three times 
in 0.15 M saline and resuspended in saline to 5% (v/v). To 
5 ml of a 5% RBC suspension, 5 ml of detoxified LPS solution 
(50 ug per ml in 0.067 M PBS) was added. The LPS-RBC 
mixture was incubated for 2 h at 37° C with periodic mixing. 
Sensitized RBC's were sedimented and washed one time in PBS. 
Serial two-fold dilutions of heat inactivated test sera were 
made in 0.5 ml volumes. Heat-inactivated prebleed sera and 
normal rabbit (obtained from RBC donors) sera were used as 
the negative controls. To each serum dilution, 0.5 ml of a 
0.5% suspension of sensitized RBCs were added, and each tube
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was vortexed gently. The tubes were incubated at 37° C for 
ninety minutes and examined for agglutination. The tubes 
were reincubated at 4° C for 24 h and read again for 
agglutination.
Results and Discussion
Three different whole cell vaccines were used to 
immunize rabbits in attempts to produce high titered anti-V 
vulnificus polyclonal sera. Rabbits immunized with 
formalinized, heat-killed or acetone dried cells all 
produced uniformly low anti-LPS titers in rabbits (Table 1) 
The titers were ten-fold lower than PHA titers to V. 
cholerae PS-sensitized rRBCs (Adams and Siebeling 1984).
The two possible reasons for the presence of low anti- 
LPS titer are; 1) The polysaccharide is a poor immunogen. 
2) The LPS epitopes may be covered by a capsular material, 
effectively hiding these antigens from the immune system.
To differentiate between these two possibilities PS- 
carrier conjugates were produced to eliminate the possible 
interference caused by non-immunogenic capsule present on 
the surface of the whole cell vaccines. Two different 
procedures were employed to couple PS to protein carrier; 
the CnBr procedure used by Adams and Siebeling (1984) and 
the benzoquinone procedure used by Brandt et al.(1975). 
Rabbits immunized with these PS-carrier conjugates produced 
low titers for V. vulnificus LPS (Table 1). These results 
suggest that the LPS of V. vulnificus is significantly less 
immunogenic than LPS prepared from V. cholerae (Adams and 
Siebeling 1984). There are numerous reports of LPS acting
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TABLE 1. O-tube agglutination and PHA titers produced in 
rabbits immunized with whole cells vaccines and PS-protein 
carrier conjugates prepared from V. vulnificus 1005.
Agglutination Titers 
Antigen Technique Titer
Formalinized cells (I.V.) "0" Agg.a 160
Acetone dried cells (I.V.) "0" Agg. 320
Heat killed cells (I.V.) PHAb 8
PS-BGG conjugated with CnBr PHA 256
PS-BGG conjugated with Benzoquinone PHA 128
a= 0-Tube agglutination 
b= Passive Hemagglutination
c= reciprocal of the greatest dilution of sera which 
exhibits a discernable reaction.
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as an adjuvant and also acting as a suppressor of the In­
dependent primary immune response (Persson, 1977; Sjoberg, 
et al. 1972). LPS has been reported to be able to activate 
macrophages while at the same time it may inhibit T- 
lymphocyte transformation (Nelson 1973). It is possible, 
however, that the V. vulnificus LPS is a poor immunogen due 
to it's chemical structure. It is possible that non- 
immunogenic capsular carbohydrate was co-purified with LPS, 
diluting the immunogenicity of the LPS.
In summary, conventional whole vaccines or PS-protein 
carrier conjugates do not provoke an acceptable level of 
anti-LPS activity in the rabbit. When low titer antiserum 
is used in slide agglutination tests to serotype unknown V. 
vulnificus isolates, undiluted serum may have to be used, 
which may decrease specificity.
Chapter III Serotyping of Vibrio vulnificus Using 
Lipopolysaccharide Specific Monoclonal Antibodies
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Abstract
A serotyping scheme for V. vulnificus based on 
monoclonal antibodies specific for lipopolysaccharide (LPS) 
antigens is proposed. Previous typing schemes for V. 
vulnificus have used heat-killed whole cell vaccines to 
produce polyclonal antisera. Polyclonal antisera produced 
in this way cross-reacts with most heterologous strains. 
Affinity purification of polyclonal antisera, using LPS 
affinity columns, resolved some of these cross-reactions, 
however, affinity-purified polyclonal antisera still showed 
cross-reactions that were non-reciprocal. On the basis of 
the initial results with the affinity-purified polyclonal 
antisera, strains were selected for the production of 
monoclonal antibodies. Balb/c mice were immunized with 
formalinized whole cells. Spleenocytes were collected from 
immunized mice and fused with SP2/0-Ag 14 myeloma cells. 
Hybridomas were screened using both lipopolysaccharide and 
whole cell ELISAs to select clones secreting LPS specific 
antibodies. This approach was expanded to include Vibrio 
damsela and Vibrio hollisae.
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introduction
Infections caused by V. vulnificus have been reported 
in most parts of the world (Matsuo et al. 1978; Mertens et 
al. 1979; Blake et al. 1979; Blake et al. 1980; Ghosh and 
Bowen 1980). Environmental surveys of V. vulnificus in the 
United States show that V. vulnificus is found in virtually 
all coastal areas during the warmer months of the year 
(Matsuo et al. 1978; Blake et al. 1980; Ghosh and Bowen 
1980; Kelly 1982; Oliver et al. 1982; Oliver et al. 1983). 
Because of the widespread distribution of V. vulnificus and 
its virulence for certain patient groups, rapid detection of 
this organism is becoming increasingly important.
A species specific flagellar (H-antigen) antigen has 
been identified and used in the rapid identification of V. 
vulnificus (Tassin et al. 1983; Simonson and Siebeling 1986; 
Simonson and Siebeling 1988). Shimada and Sakazaki (1984) 
described a serotyping scheme based on direct agglutination, 
of whole heat killed V. vulnificus cells with polyclonal 
antisera raised in rabbits. Because heat destroys the H- 
antigens, the agglutination reactions observed were assumed 
to represent reactions between cell wall associated O- 
antigen and antiserum. The surface of the bacterial cell 
presents various potential antigens to the rabbit's immune 
system, therefore, antibodies directed against outer
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material are produced. The inability to raise high titered 
anti-LPS activity have made the use of polyclonal antisera 
inefficient. To date, a serotyping scheme based on 
detection of lipopolysaccharide (LPS) antigens has not been 
established for V. vulnificus.
Vibrio vulnificus has a capsule that covers the outer 
membrane (Amako et al. 1984; Yoshida et al. 1985). Because 
the capsule may interfere with serological tests designed to 
detect LPS determinants, both opaque (encapsulated) and 
translucent (non-encapsulated) variants of V. vulnificus 
were tested to determine the effect that this capsule would 
have on LPS ELISAs done with LPS specific monoclonal 
antibodies.
We propose a serotyping scheme based on purified LPS, 
extracted from V. vulnificus. Six hybridomas have been 
established that produce LPS-specific antibody and react 
with whole cells of six O-serovars by ELISA. In addition to 
V. vulnificus, monoclonal antibodies were also produced 
against LPS extracted from V. damsela and V. hollisae.
These last two organisms were included because they are also 
pathogenic for humans and cause infections that may resemble 
V. vulnificus infection. V. carchariae was used as a non­
human pathogen Vibrio control. No reports of human 
infection with this organism exist.
Materials and Methods
Bacterial Strains Studied. The following isolates were used 
in this study: V. vulnificus strains: ATCC 27526, Louisiana 
Department of Health and Human Resources (DHHR) strains 
numbered: 846, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 
1007, 1008, 1009 1010, 1012, 1013, 1014, and 1015, CDC 
strain E4125, V. hollisae ATCC 33564, V. damsela ATCC 35083, 
V. carchariae ATCC 35084. The variants Vvl005 opaque (0) 
and Vvl005 translucent (T) were derived from DHHR strain 
1005.
Production of Polyclonal Antisera. Outbred New Zealand 
white rabbits were immunized with formalinized whole cell 
vaccines. V. vulnificus cells were cultured on alkaline 
peptone agar (1% peptone, 1.5% agar, 2% NaCl, 0.2% Yeast 
Extract, Difco Laboratories, Detroit Michigan) at 37° C for 
twenty-four hours. Cells were harvested in 0.15 M NaCl 
(saline) supplemented with .5% formaldehyde and held at 4° C 
for forty-eight hours. Each vaccine was inoculated into 
thioglycolate broth (Difco Laboratories, Detroit, Michigan), 
incubated at 37° C for twenty-four hours to insure that 
cells were killed. Vaccines which showed no growth in 
thioglycolate broth were sedimented and resuspended in 0.067 
M PBS to a concentration of 1010 cells per ml. Rabbits were 
immunized with 1 . 0  ml of standardized vaccine every two 
days for a period of three weeks. On day twenty-five, blood 
was collected, serum was harvested and stored at -20° C
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until used.
LPS Extraction. LPS was extracted from 1 to 5 grams of 
acetone dried whole Vibrio cells. The Vibrio cells were 
grown on alkaline peptone agar at 30° C for 48 h and 
harvested in 0.15 M NaCl. The cells were washed twice in 
0.15 M NaCl, resuspended in acetone and held at room 
temperature overnight. The cells were washed twice with 
acetone and dried at room temperature. The dried cells were 
ground to a fine powder with a mortar and pestle. The LPS 
was extracted using the phenol-water extraction procedure 
of Westphal and Jann (1965). The LPS (1 mg per ml) was 
detoxified by treatment with 0.25 N NaOH at 37° C for 4 h, 
followed by 1 h at 56° C. The detoxified material was 
neutralized by dialysis against 0.067 M PBS at 4° C 
overnight. For use in ELISA, the LPS solution which 
contained both lipid and polysaccharide (PS) was resuspended 
to 50 ug per ml (LPS) in 0.067 M PBS, pH 7.3 and stored at - 
20° C. A PS preparation was obtained by centrifugation of 
the detoxified material at 1 0 0 , 0 0 0  x g to sediment the 
lipid. The supernatant, which contained the PS, was 
lyophilized.
LPS Affinity Columh Preparation. The purified PS was 
coupled to an amino-hexyl sepharose matrix by a benzoquinone 
bridge by the method of Girard and Goichot (1981). The 
column was equilibrated with 0.067 M PBS, pH 7.3 starting 
buffer until a consistent O.D. was established at 280 nm.
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One ml of the whole anti-V. vulnificus serum was applied 
directly to the top of the column and allowed to enter the 
bed. The serum was retained in the matrix for one hour at 
room temperature to permit anti-LPS antibody absorption to 
the LPS-matrix. Unbound proteins were eluted with starting 
buffer until the absorption at 280 nm had returned to 
baseline. The bound anti-LPS fraction was eluted with a 0.2 
M glycine buffer pH 2.8. The column was re-equilibrated 
with starting buffer to pH 7.3. The eluted anti-LPS 
proteins were dialyzed against starting buffer to neutralize 
the pH and concentrated to the original volume (1 ml). Each 
column was used repeatedly over a period of several weeks, 
then the matrix was retrieved and stored at 4° C in 0.067 M 
PBS pH 7.3 with 0.2% NaN3 added as a preservative.
Monoclonal Antibody Production. Monoclonal antibody 
secreting hybridomas were produced by fusing immune 
spleenocytes collected from female Balb/c mice with non-Ig 
secreting SP2/0-Agl4 cells (American Type Culture 
Collection, Rockville, Md.). The fusion protocol used was a 
modification of the method used by Oi and Herzberg (1980). 
Cells were fused in a ratio of four spleenocytes to one 
myeloma cell in 50% polyethylene glycol M.W. 1500 in 75 mM 
HEPES buffer (Boehringer Mannheim Biochemicals,
Indianapolis, Ind.). Following fusion the cells were 
suspended in RPMI medium supplemented with 2 mM glutamine 
(Flow Laboratories, McLean, Va.), 0.2% NaC03 (Flow
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Laboratories, McLean, Va.), 1% Non-essential amino acids 
(Flow Laboratories, McLean, Va.), 1% Hypoxanthine-Thymidine 
(HT) (GIBCO, Grand Island, N.Y.), and 15% Fetal Bovine Sera 
(FBS)(GIBCO, Grand Island, N.Y.). The fused cells were 
delivered to 96 well plates previously seeded with a feeder 
layer of Balb/c thymocytes (lx 106 cells per well). During 
the first week following fusion the cells were fed twice 
with 100 ul RPMI supplemented with Hypozanthine-Aminopterin- 
Thymidine (HAT) (GIBCO, Grand Island, New York) and FBS. At 
the end of the first week, cells were fed with 100 ul RPMI 
supplemented with HT and FBS. Medium supplemented with HT 
was used to feed the cells until the cells were cloned by 
limiting dilution. At the end of the second week, culture 
supernatant fluids from each well which contained a 
developing hybridoma was screened for antibody production by 
both whole cell and LPS ELISA. Hybridomas in wells that 
tested positive for the desired antibody were cloned by 
limiting dilution until a stable cell line was generated. 
Whole Cell E1ISA Vibrio cells, grown on alkaline peptone 
agar at 30° C overnight, were harvested in .05 M NaHC03- 
NaC03 coupling buffer, pH 9.6. The cells were washed one 
time in coupling buffer and suspended to 3 x 108 cells per 
ml. A 50 ul aliquot was delivered to each well of a 96 well 
polystyrene ELISA plate (Immunlon II; Dynatech Laboratories, 
Inc., Alexandria, Va.). The plates were incubated 
overnight, uncovered, at 37° C. The wells were blocked by
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the addition of 200 ul of 2% BSA in Tris-EDTA-NaCl buffer 
(TEN)(0.05 M TRIS-HCL, 0.001 M EDTA, 0.15 M NaCl,pH 7.2) for 
30 minutes at 37° C. The wells were washed one time with 
TEN buffer and then 50 ul of test fluid or control sera was 
added to each well and incubated at 37° C for 30 minutes.
The wells were washed one time to remove unbound antibody 
and 50 ul of anti-mouse Ig-phosphatase conjugate (Sigma 
Chemical Company, St. Louis, Mo.) diluted 1:200 in TEN 
buffer supplemented with 2% BSA was added to each well. The 
plates were incubated for 30 minutes at 37° C, and each well 
was washed five times with TEN buffer. The plates were 
patted completely dry, and 2 0 0  ul of 1 mg per ml phosphatase 
substrate (o-nitrophenyl phosphate, Sigma Chemical Company, 
St. Louis, Mo.) diluted in diethanolamine buffer (97 ml 
diethanolamine, 100 mg MgCl2.6H20, 0.2 mg NaN3 per liter) pH
9.8 was added to each well. The plates were incubated at 
37° C for 30 minutes and absorbance was read at 405 nm with 
a manual ELISA reader (Bio-Tek, Inc.). Culture supernates 
which exhibited an absorbance of 0 . 2 or greater were 
considered positive.
LPS ELISA. The LPS ELISA's were done using the protocol 
described above with the following modifications.
Detoxified LPS, diluted to 50 ug per ml in PBS, pH 7.3, was 
used as antigen (both PS and lipid moieties were present). 
Polyvinyl chloride microtiter plates (Dynatech Laboratories 
Inc., Alexandria, Va.) were coated with 50 ul of LPS (2.5 ug
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LPS per well) and Incubated at 37° C overnight to dry. The 
protocol stated above was followed using either PBS or TEN 
buffer as the wash solution.
Results
Polyclonal V. vulnificus antiserum raised in rabbits 
immunized with whole cell vaccines produced slide 
agglutination patterns that were non-reciprocal and non­
specific (Table 1). These findings were consistent with 
reports in the literature (Shimada and Sakazaki 1984) and 
our previous experience* The two traditional methods used 
to remove cross-reactivity from polyclonal serum are 
dilution and absorption. Polyclonal antiserum produced in 
rabbits against V. vulnificus exhibited low agglutination 
titers, usually < 1280 by Passive Hemagglutination or <320 
by O-antigen agglutination. Because of the low titers, 
dilution of the sera did not eliminate cross-reactions.
When these sera were used in slide agglutination tests a 1:5 
dilution of polyclonal antiserum results in the loss of 
serological activity.
Anti-LPS activity was eluted from amino-hexyl 
sepharose-LPS affinity columns. Direct bacterial slide 
agglutinations tests were done with the affinity purified 
anti-LPS antibody with both formalinized and live Vibrio 
cell suspensions as antigen. In most instances, killed 
bacteria showed stronger agglutination patterns than did 
live organisms (Table 2). The number of cross-reactions was 
reduced in all five sera tested and eliminated in the case 
of W1008, however, some non-specific agglutination was 
still present.
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TABLE 1. Agglutination patterns for 5 anti-V. vulnificus 
sera raised in rabbits immunized with formalinized whole 
cell vaccines and tested against vaccine strains.
Vaccine Strains 
Suspended in FPBS
anti-
1 0 0 2
anti-
1003
anti-
1005
anti-
1006
anti-
1008
Vvl002 ++ + + + +
W1003 + ++ + 0 ++
W 1 0 0 5 0 ++ ++ ++ ++
W 1 0 0 6 0 ++ ++ ++ ++
W 1008 0 0 0 ++ ++
VvATCC 27562 0 ++ ++ ++ ++
++= Immediately discernable agglutination 
+= Weak/Delayed agglutination 
0= No discernable reaction
6 8
TABLE 2. Slide agglutination patterns for five affinity 
purified anti-V. vulnificus-PS sera. Antibody eluted from 
AH-Sepharose armed with PS extracted from each of the 
vaccine strains. Test antigen was whole cells suspended in 
0.3% formalinized PBS (fixed) and saline (live).
vaccine anti- 1 0 0 2 anti- 1003 anti- 1005 anti- 1006 anti -1008
strains F L F L F L F L F L
W 1 0 0 2 ++ ++ 0 0 0 0 0 0 0 0
W1003 ++ 0 ++ ++ 0 0 0 0 0 0
VV1005 0 + ++ ++ ++ + ++ ++ 0 0
Vvl006 0 0 ++ 0 ++ 0 ++ ++ 0 0
W1008 0 + 0 0 0 0 0 0 ++ ++
VvATCC ++ 0 ++ 0 ++ + 0 0 0 0
++= Immediately discernable agglutination 
+= Weak/Delayed agglutination 
0= No discernable reaction 
F= Fixed 
L= Live
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These findings (Table 2) were used as the basis for 
selection of V. vulnificus strains to be used to 
produce monoclonal antibodies. The cross-agglutination 
reactions between anti-W1005 and anti-Vvl006 was strong and 
reciprocal, and as a result, only strain Vvl005 was selected 
as a candidate for monoclonal antibody production. 
Agglutination patterns of strains Vvl002 and Vvl008 
suggested that these two isolates represented distinct LPS 
serovar which were distinct from Vvl005.
Hybridoma clones were screened by both a whole cell and 
LPS ELISA. Both approaches were tested for two reasons. 
First, the Westphal LPS extraction procedure may have 
altered or degraded LPS epitopes. It was prudent therefore 
to test culture supernates clones reactivity not only 
against purified LPS but, also against whole cells (native 
LPS). Second, LPS reactive Mab might not be the only 
activity of value. It would be possible to identify clones 
that had strong reactivity against whole cells but, were 
non-reactive against LPS. Such Mab's might recognize 
epitopes on other cell surface antigens that may have been 
responsible for cross reactivity observed with polyclonal 
antiserum. In the LPS ELISA, both the polysaccharide and 
the lipid portion of the LPS molecule were present which 
provided the opportunity to identify anti-Lipid A or anti­
core oligosaccharide Mab's, which should react with each 
LPS preparation. No activity specific for lipid A or core-
TABLE 3. Serological specificity of monoclonal antibodies
versus polyclonal 
antigens.
antisera for LPS (0--serovar specific)
V. vulnificus Anti-Vvl002 Anti- 1005
LPS Polyclonal Monoclonal Polyclonal Monoclonal
Vv 846 0 0 ++ 0
VvlOOO 0 0 ++ 0
W 1 0 0 1 + 0 ++ 0
W 1 0 0 2 ++ ++ ++ 0
Vvl003 ++ 0 + 0
W 1004 ++ 0 + 0
W 1 0 0 5 + 0 ++ ++
Vvl006 0 0 ++ ++
W 1 0 0 7 + ++ ++ 0
VV1008 + 0 ++ 0 •
Vvl009 0 0 + 0
VvlOlO + 0 ++ 0
W 1012 + 0 + 0
W1013 + 0 + 0
W1014 + 0 + 0
W 1 0 1 5 + 0 + 0
WE4125 + ++ ++ 0
VvATCC 27562 + 0 + ++
a 
a
Q 
Qa 
a
o 
o
1! 
II 
+ 
+ +
0 . 2
1 . 0
@ 405 nm. 
@ 405 nm.
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oligosaccharide was detected.
Lipopolysaccharide ELISA titrations were done using 
both polyclonal sera and Mab. These experiments showed that 
unique LPS epitopes could be identified and that Mab did not 
exhibit the cross reactions (Table 3).
Six different LPS serovars have been identified by LPS 
ELISA within the 16 V. vulnificus isolates examined. 
Monoclonal antibodies have been produced that react with 
five of these six serovars (Table 4). Monoclonal antibody 
was produced that reacted with LPS extracted from V. damsela 
and V. hollisae. which were non-reactive with the V. 
vulnificus LPS's.
The V. vulnificus LPS serovars identified, thus far, 
have been assigned numbers 1 through 6 predicated on ELISA 
titers run with either monoclonal or affinity purified anti- 
LPS antibodies (Table 5).
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TABLE 4. Hybridomas producing V. vulnificus lipopoly- 
saccharide-specific monoclonal antibody. Determined by LPS 
ELISA of cell culture supernates.
Anti-LPS Hybridomas
LPS SM-3 SM-1 SM-29 SM-11 SM-3 9 SM-15 SM-19
W 1 0 0 0 0 c 0 0 0 0 0 0
VvlOOl ++d 0 0 0 0 0 0
Vvl002 0 ++ 0 0 0 0 0
Vvl003 0 0 0 0 0 0 0
Vvl004 0 0 ++ 0 0 0 0
Vvl005 0 0 0 ++ 0 0 0
Vvl006 0 0 0 ++ 0 0 0
Vvl007 0 ++ 0 0 0 0 0
W 1 0 0 8 0 0 0 0 0 0 0
VV1009 0 0 0 0 ++ 0 0
W 1 0 1 0 0 0 0 0 0 0 0
VV1012 0 0 0 0 0 0 0
W 1013 0 ++ 0 0 0 0 0
W 1 0 1 5 0 0 0 0 0 0 0
VvE4125 0 ++ 0 0 0 0 0
VvATCCa 0 0 0 ++ 0 0 0
V.damsela 0 0 0 0 0 ++ 0
V.hollisaeO 0 0 0 0 0 ++
Negativeb 0 0 0 0 0 0 0
®= V. vulnificus ATCC type strain #27562 
= V. carchariae LPS ( Vibrio species not associated with 
human disease)
*= Negative LPS ELISA, O.D.< 0.2 
d= Positive LPS ELISA, O.D.> 1.0
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TABLE 5. Proposed serological varieties of V. vulnificus 
based on lipopolysaccharide specific monoclonal antibodies.
Serovar MAb Strain Incidence %
1 SM-11 Vvl005 3/16 19
2 SM-3 VvlOOl 1/16 6
3 SM-1 W1002 2/16 12
4 SM-29 W1004 1/16 6
5 SM-3 9 W 1009 1/16 6
6a N. A. VV1008 2/16 1 2 b
a= Tentative serovar based on affinity purified polyclonal 
b= 61% of Louisiana V. vulnificus strains tested fall into 
these six LPS serovars.
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Whole cell preparations of the translucent and opaque 
phenotypes of V. vulnificus and their respective LPSs were 
tested by both LPS and whole cell ELISA to determine if the 
presence of capsule (more abundant in opaque strains) 
interfere with the serological activity of anti-LPS. V. 
vulnificus isolate 1005 was tested because opaque and 
translucent cells and polyclonal antisera and Mab were 
available. The highest dilution that produced a 0.2 
absorbance or greater was read as the endpoint (Table 6 ).
The presence of capsule interfered with the activity of both 
polyclonal antisera and Mabs. A sixteen-fold reduction in 
the activity of Mab SM-11 against whole opaque cells as 
compared to translucent cells was observed. There was no 
difference in the LPS ELISA titers for LPS extracted from 
opaque and translucent cells.
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TABLE 6 . ELISA titers for opaque and translucent V. 
vulnificus whole cells and LPS extracted from opaque and 
translucent V. vulnificus cells vs. polyclonal and 
monoclonal sera.
V. vulnificus 1005 Rabbit antiserum Mab
Colony Type Antigen 1005 1005-0 1005—T SM-11
Opaque LPS 32,000 64,000 256,000 4,000
Translucent LPS 32,000 64,000 256,000 4,000
Opaque Cells 8 , 0 0 0 8 , 0 0 0 8 , 0 0 0 4,000
Translucent Cells 16,000 16,000 16,000 64,000
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Discussion
Polyclonal antisera was found unacceptable for the 
serological typing of V. vulnificus. Affinity purified 
polyvalent anti-LPS did not exhibit the magnitude of cross 
reactions that were seen with the whole antiserum (Tables 1 
& 2 ). It was possible to use affinity purified anti-LPS 
sera to select V. vulnificus strains to be used to produce 
monoclonal antibodies. Affinity purification worked well 
for some anti-LPS preparations. Polyclonal anti-Vvl008 
serum which reacted with all strains tested was rendered 
specific for 1008 cells when anti-1008 was affinity 
purified. Because antisera raised to V. vulnificus usually 
exhibit low anti-LPS PHA titers, with PHA titers < 1280 
compared to titers of 160,000 obtained with V. cholerae Non- 
01 (Adams and Siebeling 1984), the serum could not be 
diluted to reduce non-specific cross-reactions.
Monoclonal antibodies which react with LPS can be used 
to serotype either the opaque or translucent phenotypes of 
V. vulnificus (Table 5). ELISA titers suggest that the LPS 
epitopes are more readily accessible on the surface of the 
translucent cell than on the opaque cell. This finding 
suggests that the capsule or slime layer present on the 
opaque cell may block access of the monoclonal antibody to 
the LPS.
The five anti-V. vulnificus LPS Mab's produced
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recognize only 50% of the 16 V. vulnificus isolates tested. 
These results indicate that there is more heterogeneity in 
V. vulnificus LPS than was previously reported (Shimada and 
Sakazaki 1984). Since the majority of the isolates used in 
this study were recovered in Louisiana there maybe a greater 
distribution of LPS antigens than these findings indicate. 
Preliminary results obtained with Mab reactive with LPS from 
V. damsela and V. hollisae did not react with LPS prepared 
from V. vulnificus, which suggests that these two marine 
Vibrios express unique LPS 0 determinates. Due to the small 
number of strains tested no accurate correlation between LPS 
antigens and virulence can be made.
Vibrio vulnificus isolates can be serotyped by 
utilizing LPS specific Mab. To be of value in 
epidemiological and environmental studies, the typing scheme 
will have to be expanded to completely cover the possible 
LPS serovars presented by this organism.
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